Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion
Authors:
- 1 September 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 35 (7) , 407-412
Abstract
Purpose: To investigate aqueous humor levels of 11 factors/cytokines in patients with central retinal vein occlusion (CRVO) and macular edema (ME) receiving anti-vascular endothelial growth factor (VEGF) therapy, as well as correlations between changes of functional or morphological parameters and aqueous cytokine levels. Methods: In 32 CRVO patients scheduled to receive 2 consecutive doses of intravitreal ranibizumab, aqueous samples were obtained at the time of injecting each dose. Aqueous levels of VEGF, soluble VEGF receptor (sVEGFR)-1, sVEGFR-2, platelet-derived growth factor-AA (PDGF-AA), placental growth factor (PlGF), interleukin-6, and monocyte chemotactic protein-1 (MCP-1) were measured using a suspension array. Results: Aqueous humor levels of VEGF, sVEGFR-1, PDGF, PlGF, interleukin-6, and MCP-1 were all significantly lower at 1 month after the initial dose of intravitreal ranibizumab compared with baseline. A significant negative correlation was noted between the change of ME and the changes of aqueous humor VEGF or interleukin-6 levels after intravitreal ranibizumab. The change of VEGF also showed a significant negative correlation with improvement of visual acuity. Conclusions: In patients with CRVO, the changes of visual acuity and ME after intravitreal ranibizumab were associated with inhibition of intraocular VEGF production. VEGF could be a useful marker for the response of ME to treatment.Keywords
This publication has 36 references indexed in Scilit:
- The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinomaOncology Reports, 2012
- Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic TherapiesGenes & Cancer, 2011
- Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III StudyOphthalmology, 2011
- The nuclear factor- B-interleukin-6 signalling pathway mediating vascular inflammationCardiovascular Research, 2010
- VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage RecruitmentArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Vascular Endothelial Growth Factor and Its Relationship to Inflammatory MediatorsClinical Cancer Research, 2007
- Effect of berberrubine on interleukin-8 and monocyte chemotactic protein-1 expression in human retinal pigment epithelial cell lineLife Sciences, 2006
- Rapid disruption of gap junctional communication and phosphorylation of connexin43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptorJournal of Cellular Physiology, 1998
- The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological ActivitiesJournal of Biological Chemistry, 1996
- Interleukin 6 Induces the Expression of Vascular Endothelial Growth FactorJournal of Biological Chemistry, 1996